At the end of February 2019, Dr. Lundy was forced to close his lab at the University of Michigan Medical School due to insufficient funding. He has since taken a position as a Principal Scientist at SystImmune, a biotech company in Redmond, Washington that specializes in cancer immunotherapy. He maintains an Adjunct Associate Professor appointment at the University of Michigan and can still be reached at sklundy@umich.edu.